I

n a victory for the European Medicines Agency, a European court ruled the regulator can provide access to clinical trial data and other types of information over the objections of three drug makers that claimed greater transparency would come at the expense of their commercial secrets.

The cases have been closely watched as a test of transparency rules that the EMA implemented seven years ago, as well as a newer policy that permits the agency to release certain clinical trial data, while also agreeing to select redactions negotiated with companies.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that since this is a European matter, the ‘Merck’ in question might be more properly tagged “MS&D?” (Merck Sharp & Dhome)
    That takes nothing away from the valuable detail in the article, which one expects will be updated as usual by additional company comments, as they arrive.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.